Heather I Henderson1,2, Sonia Napravnik1,2, Emily W Gower1, Allison E Aiello1, Alan C Kinlaw3,4, Billy Williams5, David A Wohl2, David van Duin2. 1. Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA. 2. Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA. 3. Division of Pharmaceutical Outcomes and Policy, University of North Carolina at Chapel Hill School of Pharmacy, Chapel Hill, North Carolina, USA. 4. Cecil G. Sheps Center for Health Services Research, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USAand. 5. Clinical Microbiology Laboratory, University of North Carolina Hospitals, Chapel Hill, North Carolina, USA.
Abstract
BACKGROUND: Multidrug-resistant Enterobacterales (MDR-E) are important pathogens. People living with human immunodeficiency virus (HIV; PLWH) may be at greater risk for MDR-E infection given relatively high antibiotic exposure and burden of comorbidities. METHODS: We analyzed data from 36 521 patients in a healthcare system in North Carolina who had a clinical culture with growth of an Enterobacterales species from 2000 to 2018; 440 were PLWH. We used generalized linear models to estimate prevalence ratios and differences, contrasting PLWH and people not living with HIV (PNLWH) for resistance to individual antibiotic classes, as well as MDR-E. We assessed trends in prevalence over time by calculating the 5-year moving average and fitting restricted cubic spline models. RESULTS: The overall prevalence of MDR-E was higher among PLWH (21.5%; 95% confidence interval [CI], 18.2%-25.1%) vs PNLWH (16.5%; 95% CI, 16.2%-16.9%), with an adjusted prevalence ratio of 1.38 (95% CI, 1.14-1.65). PLWH had higher rates of antimicrobial resistance than PNLWH for all antibiotic classes analyzed, including penicillins, penicillin/beta lactamase inhibitor combinations, and sulfonamides. MDR-E prevalence was 3 to 10 percentage points higher among PLWH than PNLWH throughout the study period based on the 5-year moving average. CONCLUSIONS: In a large clinical study population in the southeastern United States from 2000 to 2018, the prevalence of antibacterial resistance among Enterobacterales was consistently higher among PLWH than PNLWH. These data highlight the importance of identifying and mitigating the factors that contribute to antimicrobial resistance in PLWH, given the potential clinical consequences of these resistant pathogens.
BACKGROUND: Multidrug-resistant Enterobacterales (MDR-E) are important pathogens. People living with human immunodeficiency virus (HIV; PLWH) may be at greater risk for MDR-E infection given relatively high antibiotic exposure and burden of comorbidities. METHODS: We analyzed data from 36 521 patients in a healthcare system in North Carolina who had a clinical culture with growth of an Enterobacterales species from 2000 to 2018; 440 were PLWH. We used generalized linear models to estimate prevalence ratios and differences, contrasting PLWH and people not living with HIV (PNLWH) for resistance to individual antibiotic classes, as well as MDR-E. We assessed trends in prevalence over time by calculating the 5-year moving average and fitting restricted cubic spline models. RESULTS: The overall prevalence of MDR-E was higher among PLWH (21.5%; 95% confidence interval [CI], 18.2%-25.1%) vs PNLWH (16.5%; 95% CI, 16.2%-16.9%), with an adjusted prevalence ratio of 1.38 (95% CI, 1.14-1.65). PLWH had higher rates of antimicrobial resistance than PNLWH for all antibiotic classes analyzed, including penicillins, penicillin/beta lactamase inhibitor combinations, and sulfonamides. MDR-E prevalence was 3 to 10 percentage points higher among PLWH than PNLWH throughout the study period based on the 5-year moving average. CONCLUSIONS: In a large clinical study population in the southeastern United States from 2000 to 2018, the prevalence of antibacterial resistance among Enterobacterales was consistently higher among PLWH than PNLWH. These data highlight the importance of identifying and mitigating the factors that contribute to antimicrobial resistance in PLWH, given the potential clinical consequences of these resistant pathogens.
Authors: F Kontopidou; H Giamarellou; P Katerelos; A Maragos; I Kioumis; E Trikka-Graphakos; C Valakis; H C Maltezou Journal: Clin Microbiol Infect Date: 2013-08-30 Impact factor: 8.067
Authors: A-P Magiorakos; A Srinivasan; R B Carey; Y Carmeli; M E Falagas; C G Giske; S Harbarth; J F Hindler; G Kahlmeter; B Olsson-Liljequist; D L Paterson; L B Rice; J Stelling; M J Struelens; A Vatopoulos; J T Weber; D L Monnet Journal: Clin Microbiol Infect Date: 2011-07-27 Impact factor: 8.067
Authors: David van Duin; Federico Perez; Susan D Rudin; Eric Cober; Jennifer Hanrahan; Julie Ziegler; Raymond Webber; Jacqueline Fox; Pamela Mason; Sandra S Richter; Marianne Cline; Geraldine S Hall; Keith S Kaye; Michael R Jacobs; Robert C Kalayjian; Robert A Salata; Julia A Segre; Sean Conlan; Scott Evans; Vance G Fowler; Robert A Bonomo Journal: Antimicrob Agents Chemother Date: 2014-05-05 Impact factor: 5.191
Authors: Zubair A Qureshi; David L Paterson; Brian A Potoski; Mary C Kilayko; Gabriel Sandovsky; Emilia Sordillo; Bruce Polsky; Jennifer M Adams-Haduch; Yohei Doi Journal: Antimicrob Agents Chemother Date: 2012-01-17 Impact factor: 5.191
Authors: Sergio Serrano-Villar; Félix Gutiérrez; Celia Miralles; Juan Berenguer; Antonio Rivero; Esteban Martínez; Santiago Moreno Journal: Open Forum Infect Dis Date: 2016-05-12 Impact factor: 3.835
Authors: Heather I Henderson; Laura Ruegsegger; Kevin Alby; Jason R Smedberg; Bravada M Hill; Dylan Brown; David A Wohl; Sonia Napravnik; David Van Duin Journal: JAC Antimicrob Resist Date: 2022-08-02
Authors: Heather I Henderson; Sonia Napravnik; Michael R Kosorok; Emily W Gower; Alan C Kinlaw; Allison E Aiello; Billy Williams; David A Wohl; David van Duin Journal: Open Forum Infect Dis Date: 2022-09-17 Impact factor: 4.423